FDA Plans to Speed Path to Approval for Some Gene Therapies – Scientific American
Scientific American |
FDA Plans to Speed Path to Approval for Some Gene Therapies
Scientific American Specifically, gene therapies for hemophilia, a rare disease in which blood doesn't clot properly because it lacks certain proteins, could be evaluated based on whether therapy increases those proteins in the blood, regardless of whether the therapy … What We're Reading: "Right-to-Try" Law Set; FDA to Speed Gene Therapies; Drug Pricing Analysis Finds Increases Trending News Today: Congress Passes Right to Try Legislation for Terminally Ill Patients |
